Azenta, Inc. (AZTA) fair value analysis
Nasdaq · Updated 2026-10-19
AZTA price how computed
Forward Fair Value verdict
OvervaluedAZTA is trading at a 10–25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $34.09
- Sector
- Healthcare
- 12-month range
- $16.02–$42.73
- Market cap
- $1.49B
- From 52-week high
- -20.2%
- Shares outstanding
- 43.8M
- Rank in Healthcare by discount to fair value
- #107 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Azenta, Inc. is a healthcare company that provides sample management and storage solutions, including cryogenic freezers and biorepository services, primarily serving life sciences research, clinical diagnostics, and pharmaceutical development organizations. The company operates globally with facilities and customers across North America, Europe, and Asia-Pacific regions.
AZTA currently ranks #107 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $1.49B
- P/E (trailing)
- 81x
- Revenue (TTM)
- $614M
- Net margin
- -20.0%
- EPS (TTM)
- $0.42
- Gross margin
- 44.9%
- Debt / equity
- 0.04
- Revenue growth (3-yr avg)
- -2.2%
- Shares outstanding
- 43.8M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 47 · neutral
- 50-day average
- $34.19
- 200-day average
- $28.32
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Dividend
- None in the last 12 months (last ex-date 2021-12-02)
Earnings how computed
- Next earnings report
- 2026-11-20
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+60.0%)
2026-03 ▼ miss (-128.6%)
2025-12 ▼ miss (-30.8%)
2025-09 ▲ beat (+5.0%)
2025-06 ▲ beat (+35.7%)
2025-03 ▼ miss (-28.6%)
2024-12 ▲ beat (+33.3%)
2024-09 ▲ beat (+63.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 3 buy · 3 hold · 0 sell (6 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $39
- Target vs last price
- +14.4%
What our data shows for AZTA
- Our model validated 8 trailing price-to-earnings windows for AZTA, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $16.02–$42.73.
- The 14-day relative strength index sits at a neutral 47.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for AZTA
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the AZTA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — AZTA's technical positioning shifted this week as the 50/200-day trend state transitioned from uptrend to mixed, suggesting less directional clarity in the near term. The stock improved its sector discount rank, moving from 105th to 99th among healthcare companies, indicating a modest relative valuation improvement within its peer group. Despite this technical adjustment, the stock maintains an overvalued verdict according to TickrTrends' derived indicators.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — AZTA's sector positioning weakened this week, with its discount rank among Healthcare companies declining from number 93 to number 104, indicating the stock has become less attractive relative to peers on a valuation basis. The current valuation verdict remains Overvalued, suggesting the stock continues to trade at a premium relative to its fundamentals within the Healthcare sector.
- 2026-09-28 — AZTA's position within the Healthcare sector has shifted less favorably this week. The company's sector discount rank declined from 82 to 93, indicating a weaker relative valuation compared to peers, while its overall valuation verdict moved from Fairly valued to Overvalued according to TickrTrends' derived indicators.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is AZTA stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), AZTA is trading at a 10–25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is AZTA's TickrTrends verdict?
AZTA's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does AZTA compare to other Healthcare stocks?
AZTA ranks #107 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is AZTA overbought or oversold?
AZTA's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does AZTA pay a dividend?
AZTA has paid no dividend in the last twelve months; its last ex-dividend date on file was 2021-12-02.
When does AZTA report earnings next?
AZTA's next earnings report is scheduled for 2026-11-20, per the published earnings calendar.
Does AZTA usually beat earnings estimates?
Over its last 8 reported quarters AZTA beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about AZTA?
Of 6 analysts covering AZTA, 3 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $39 (+14.4% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
AZTA vs AMGN · AZTA vs BIO · AZTA vs BNTX · AZTA vs CRL · AZTA vs DGX